The family of mitogen activated protein (MAP) kinases has been well described to respond to growth factors (ERKs) as well as to a number of cytokines and stress signals (JNKs and P38 kinases). Osmolality activates all three members of the MAP kinase family. The present proposal intends to examine the hypothesis that osmolality specifically activates components of these kinase families and particularly of the c- Jun N-terminal kinases (JNKs) either alone or in combination with other components. We contend that the osmoregulated pathways subserve vital adaptive functions that allow the cells to survive in an anisotonic environment. We will examine the expression of JNK isoforms by RT-PCR and the osmotic regulation of their activity in both cultured renal cells and inner medullary tissue. Likewise, we will examine expression and activity of upstream kinase (MKK4 and/or MKK7), the MEKKs (particularly MEKK1-4), and PAKs, as well as the small molecular weight G proteins that link to this pathway, namely Rac, Cdc 42 and Ras. The dissection of the osmoregulated pathways will be complemented by the assessment of the effect of dominant negative mutants (lack of function mutants), as we have such constructs available for most of the candidate kinases and small molecular weigh G-proteins. Both transient and stable transfections will be undertaken. Their effect on cell survival will be assessed. Cell death will be determined as being either necrotic or apoptotic. The ability of the mutants to undertake adaptive response to hypertonicity including synthesis of heat shock proteins, activation of the osmotic response element, synthesis of osmolyte transporters and acute volume regulation will be assessed. Finally, the ability of renal cells to sustain an osmotic stress better than non-renal cells will be analyzed as to mechanism and differential activation of kinase pathways. These experiments should define the specifically osmoregulated components of the JNK pathway and their physiologic role in adaptation to the hypertonic environment.

Project Start
2001-04-01
Project End
2002-03-31
Budget Start
Budget End
Support Year
23
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Li, Chunling; Wang, Weidong; Rivard, Christopher J et al. (2011) Molecular mechanisms of angiotensin II stimulation on aquaporin-2 expression and trafficking. Am J Physiol Renal Physiol 300:F1255-61
Andres-Hernando, Ana; Lanaspa, Miguel A; Li, Nanxing et al. (2010) Effects of 2-bromoethanamine on TonEBP expression and its possible role in induction of renal papillary necrosis in mice. Toxicol Sci 118:510-20
Furgeson, Seth B; Simpson, Peter A; Park, Insun et al. (2010) Inactivation of the tumour suppressor, PTEN, in smooth muscle promotes a pro-inflammatory phenotype and enhances neointima formation. Cardiovasc Res 86:274-82
Wang, Weidong; Li, Chunling; Summer, Sandra et al. (2010) Interaction between vasopressin and angiotensin II in vivo and in vitro: effect on aquaporins and urine concentration. Am J Physiol Renal Physiol 299:F577-84
Schrier, Robert W (2010) Systemic arterial vasodilation, vasopressin, and vasopressinase in pregnancy. J Am Soc Nephrol 21:570-2
Lanaspa, Miguel A; Andres-Hernando, Ana; Rivard, Christopher J et al. (2009) ZAC1 is up-regulated by hypertonicity and decreases sorbitol dehydrogenase expression, allowing accumulation of sorbitol in kidney cells. J Biol Chem 284:19974-81
Schrier, Robert W (2009) Interactions between angiotensin II and arginine vasopressin in water homeostasis. Kidney Int 76:137-9
Berl, Tomas (2009) How do kidney cells adapt to survive in hypertonic inner medulla? Trans Am Clin Climatol Assoc 120:389-401
Bansal, Shweta; Lindenfeld, JoAnn; Schrier, Robert W (2009) Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail 2:370-6
Schrier, Robert W; Masoumi, Amirali; Elhassan, Elwaleed (2009) Role of vasopressin and vasopressin receptor antagonists in type I cardiorenal syndrome. Blood Purif 27:28-32

Showing the most recent 10 out of 153 publications